Christoph Correll, MD, is professor of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in New York, and Medical Director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital in New York. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City.
Professor Correll’s research and clinical work focus on the identification, characterisation and treatment of adults and youths with severe psychiatric disorders, including the prodrome, first episode, multi-episode and refractory illness phase of psychotic and mood disorders. He further focuses on psychopharmacology and comparative effectiveness, as well as the risk–benefit evaluation of psychotropic medications.
Professor Correll has authored or co-authored over 450 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received over 30 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed each year by Thomson Reuters in as one of “the most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.
Dr. Correll’s research and clinical work focus on the identification, characterization and psychopharmacological management of adults and youth with severe psychiatric disorders. His areas of expertise include schizophrenia, bipolar disorder, major depression and other psychotic, mood and autism/disruptive behavior spectrum disorders, ranging from the prodrome to first episode, multi-episode and refractory illness patients. His work focuses further on the risk-benefit evaluation of psychotropic medications, including the interface between psychiatry and medicine and investigations of the extent and mechanisms of neuromotor and cardiometabolic adverse effects.
Dr. Correll and his team are conducting several studies on beneficial effects and side effects of antipsychotics and mood stabilizers; symptomatic, diagnostic and functional outcomes of youth with psychiatric problems and on clinical and biological risk factors and protective factors predicting outcomes. These research projects involve naturalistic and randomized treatment, controlled and observational studies.
SATIETY study (sponsor: National Institute of Mental Health): Children and adolescents (age 4-19 years) who start clinically decided antipsychotic treatment are followed in an observational cohort study design to assess the risks and benefits of these medications under real world conditions. Effectiveness, adverse effects and clinical and biological predictors of these effects are studied.
Adolescent Mood Disorder and Psychosis Study: Children and adolescents (age 12-18 years) who have a clinical diagnosis of a mood or psychosis spectrum disorder are interviewed to comprehensively characterize their psychiatric problems and followed in an observational cohort design to assess symptomatic and functional outcomes over time.
Fluoxetine versus Aripiprazole Comparative Trial (FACT): Youth (aged 12-25 years) fulfilling criteria for being at “high-risk” for psychosis are randomized in a double blind fashion to 6-months of treatment with either the antidepressant fluoxetine or the partial D2 agonist antipsychotic aripiprazole. Efficacy for symptoms, stability, adverse effects are studied.
Adjunctive Vortioxetine in Schizophrenia (AVIS): Stable adults (age 18-65 years) diagnosed with schizophrenia who have predominant negative symptoms are randomized in a double blind fashion to 4-months add-on vortioxetine, a marketed new-generation antidepressant, or placebo, while keeping all other treatment stable. Efficacy for negative symptoms cognition, other symptoms and adverse effects are studied.
MOBILITY – Metformin for Overweight & OBese ChILdren and Adolescents with BIpolar Spectrum Disorders Treated with Second-Generation AntipsYchotics (sponsor: Patient Centered Outcomes Research Institute (PCORI)): A multisite real-world, large pragmatic trial in which 1800 children and adolescents (age 8-17 years) with a lifetime history of a bipolar-spectrum diagnosis who are overweight or obese and treated with a second-generation antipsychotic are randomized to 2 years of open treatment with usual care and healthy lifestyle instruction or usual care and healthy lifestyle instruction plus metformin. Developmentally adjusted body mass index, patient centered outcomes in patietns and family members as well as symptoms and adverse effects are assessed.
Dr. Correll has authored or co-authored over 400 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Dr. Correll is the principal investigator or Steering Committee member of several large, federally funded grants and has received over 30 national and international research awards and fellowships for his work.
Free University of Berlin, Berlin, Germany
Field of study: Pre-Medicine & Medicine
Dundee University, Dundee, Great Britain
Field of study: Medicine
Neurologische Klinik GmbH, Bad Neustadt, Germany
Field of study: Neurology Residency
PGY-1, Beth Israel Medical Center, New York, NY
Field of study: Psychiatry Residency
Hillside Hospital, Glen Oaks, NY
Field of study: Psychiatry Research Residency (Chief)
Schneider Children’s Hospital, New Hyde Park, NY
Field of study: Child & Adolescent Psychiatry Fellow